Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.
List view / Grid view
Effective vancomycin concentrations can be delivered locally to methicillin-resistant Staphylococcus aureus (MRSA)-infected sites of the skin with the use of miniaturised needles. This presents opportunities for targeted delivery of medication for focal skin diseases. Here, Georgios A Sotiriou and Liv Eidsmo of the Karolinska Institutet discuss some of them.
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
Researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the FDA to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.
A new study found that infections caused by the drug resistant bacteria - methicillin-resistant Staphylococcus aureus, known as MRSA - are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.
A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSA according to scientists.
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
9 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)...
Changing the way we combat bacterial infections: Dutch biotech Micreos launches first bacteria-killing enzyme for human use against MRSA
5 November 2014 | By Micreos
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)...
12 March 2013 | By Department of Health
Chief Medical Officer says global action is needed otherwise in 20 years we could see any one of us dying following minor surgery...